Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers

Roche $RHHBY nailed some badly needed success in its late-stage campaign to build a market for its PD-L1 drug Tecentriq today, posting a win for its Phase III IMpower130 combination study on both overall survival as well as progression-free survival for a key group of lung cancer patients.